Literature DB >> 25789847

Phytochemical regulation of the tumor suppressive microRNA, miR-34a, by p53-dependent and independent responses in human breast cancer cells.

Kris G Hargraves1, Lin He1, Gary L Firestone1.   

Abstract

The tumor suppressive microRNA miR-34a is transcriptionally regulated by p53 and shown to inhibit breast cancer cell proliferation as well as being a marker of increased disease free survival. Indole-3-carbinol (I3C) derived from cruciferous vegetables, artemisinin, extracted from the sweet wormwood plant, and artesunate, a semi-synthetic derivative of artemisinin, are phytochemicals with anti-tumorigenic properties however, little is known about the role of microRNAs in their mechanism of action. Human breast cancer cells expressing wild-type (MCF-7) or mutant p53 (T47D) were treated with a concentration range and time course of each phytochemical under conditions of cell cycle arrest as detected by flow cytometry to examine the potential connection between miR-34a expression and their anti-proliferative responses. Real-time PCR and western blot analysis of extracted RNA and total protein revealed artemsinin and artesunate increased miR-34a expression in a dose-dependent manner correlating with down-regulation of the miR-34a target gene, CDK4. I3C stimulation of miR-34a expression required functional p53, whereas, both artemisinin and artesunate up-regulated miR-34a expression regardless of p53 mutational status or in the presence of dominant negative p53. Phytochemical treatments inhibited the luciferase activity of a construct containing the wild-type 3'UTR of CDK4, but not those with a mutated miR-34a binding site, whereas, transfection of miR-34a inhibitors ablated the phytochemical mediated down-regulation of CDK4 and induction of cell cycle arrest. Our results suggest that miR-34a is an essential component of the anti-proliferative activities of I3C, artemisinin, and artesunate and demonstrate that both wild-type p53 dependent and independent pathways are responsible for miR-34a induction.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  CDK4; Indole-3-carbinol; anti-proliferative response; artemisinin; artesunate

Mesh:

Substances:

Year:  2015        PMID: 25789847      PMCID: PMC4905729          DOI: 10.1002/mc.22296

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  55 in total

1.  Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets.

Authors:  Benjamin P Lewis; Christopher B Burge; David P Bartel
Journal:  Cell       Date:  2005-01-14       Impact factor: 41.582

2.  Target protein interactions of indole-3-carbinol and the highly potent derivative 1-benzyl-I3C with the C-terminal domain of human elastase uncouples cell cycle arrest from apoptotic signaling.

Authors:  Ida Aronchik; Tony Chen; Kathleen A Durkin; Marshall S Horwitz; Maria N Preobrazhenskaya; Leonard F Bjeldanes; Gary L Firestone
Journal:  Mol Carcinog       Date:  2011-10-19       Impact factor: 4.784

Review 3.  Molecular targets and anticancer potential of indole-3-carbinol and its derivatives.

Authors:  Bharat B Aggarwal; Haruyo Ichikawa
Journal:  Cell Cycle       Date:  2005-09-06       Impact factor: 4.534

4.  MicroRNA-34a suppresses cell proliferation by targeting LMTK3 in human breast cancer mcf-7 cell line.

Authors:  Guoqing Zhao; Jun Guo; Dong Li; Chengyou Jia; Wanzhong Yin; Ran Sun; Zhongwei Lv; Xianling Cong
Journal:  DNA Cell Biol       Date:  2013-09-19       Impact factor: 3.311

Review 5.  TP53 mutations in human cancers: origins, consequences, and clinical use.

Authors:  Magali Olivier; Monica Hollstein; Pierre Hainaut
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-01       Impact factor: 10.005

6.  Artemisinin inhibits gastric cancer cell proliferation through upregulation of p53.

Authors:  Hong-Tao Zhang; Yun-Long Wang; Jie Zhang; Qin-Xian Zhang
Journal:  Tumour Biol       Date:  2014-02

Review 7.  microRNA-34 family and treatment of cancers with mutant or wild-type p53 (Review).

Authors:  May Y W Wong; Yan Yu; William R Walsh; Jia-Lin Yang
Journal:  Int J Oncol       Date:  2011-03-10       Impact factor: 5.650

8.  Oxidative stress response of tumor cells: microarray-based comparison between artemisinins and anthracyclines.

Authors:  Thomas Efferth; Franz Oesch
Journal:  Biochem Pharmacol       Date:  2004-07-01       Impact factor: 5.858

9.  MicroRNA-34a modulates chemosensitivity of breast cancer cells to adriamycin by targeting Notch1.

Authors:  Xiu-juan Li; Ming-hua Ji; Shan-liang Zhong; Quan-bing Zha; Jin-jin Xu; Jian-hua Zhao; Jin-hai Tang
Journal:  Arch Med Res       Date:  2012-10-16       Impact factor: 2.235

10.  MicroRNA-34a and microRNA-21 play roles in the chemopreventive effects of 3,6-dihydroxyflavone on 1-methyl-1-nitrosourea-induced breast carcinogenesis.

Authors:  Chang Hui; Fu Yujie; Yuan Lijia; Yi Long; Xu Hongxia; Zhou Yong; Zhu Jundong; Zhang Qianyong; Mi Mantian
Journal:  Breast Cancer Res       Date:  2012-05-22       Impact factor: 6.466

View more
  16 in total

Review 1.  Plant natural modulators in breast cancer prevention: status quo and future perspectives reinforced by predictive, preventive, and personalized medical approach.

Authors:  Sona Uramova; Peter Kubatka; Zuzana Dankova; Andrea Kapinova; Barbora Zolakova; Marek Samec; Pavol Zubor; Anthony Zulli; Vanda Valentova; Taeg Kyu Kwon; Peter Solar; Martin Kello; Karol Kajo; Dietrich Busselberg; Martin Pec; Jan Danko
Journal:  EPMA J       Date:  2018-11-12       Impact factor: 6.543

Review 2.  Regulation of epithelial-mesenchymal transition through microRNAs: clinical and biological significance of microRNAs in breast cancer.

Authors:  Fu Peng; Liang Xiong; Hailin Tang; Cheng Peng; Jianping Chen
Journal:  Tumour Biol       Date:  2016-09-19

3.  Prognostic significance of MiR-34a in solid tumors: a systemic review and meta-analysis with 4030 patients.

Authors:  Fanghui Ren; Xin Zhang; Haiwei Liang; Dianzhong Luo; Minhua Rong; Yiwu Dang; Gang Chen
Journal:  Int J Clin Exp Med       Date:  2015-10-15

Review 4.  Impact of Nutrition on Non-Coding RNA Epigenetics in Breast and Gynecological Cancer.

Authors:  Rosanna H E Krakowsky; Trygve O Tollefsbol
Journal:  Front Nutr       Date:  2015-05-27

5.  Basal-like breast cancer: molecular profiles, clinical features and survival outcomes.

Authors:  Heloisa H Milioli; Inna Tishchenko; Carlos Riveros; Regina Berretta; Pablo Moscato
Journal:  BMC Med Genomics       Date:  2017-03-28       Impact factor: 3.063

Review 6.  Dietary phytochemicals in breast cancer research: anticancer effects and potential utility for effective chemoprevention.

Authors:  A Kapinova; P Kubatka; O Golubnitschaja; M Kello; P Zubor; P Solar; M Pec
Journal:  Environ Health Prev Med       Date:  2018-08-09       Impact factor: 3.674

Review 7.  Biomarkers of cancer angioprevention for clinical studies.

Authors:  Adriana Albini; Francesco Bertolini; Barbara Bassani; Antonino Bruno; Cristina Gallo; Stefano Giuseppe Caraffi; Sally Maramotti; Douglas M Noonan
Journal:  Ecancermedicalscience       Date:  2015-11-24

8.  Transcriptome analysis of genes associated with breast cancer cell motility in response to Artemisinin treatment.

Authors:  Kanchan Kumari; Sunita Keshari; Debomita Sengupta; Surendra C Sabat; Sandip K Mishra
Journal:  BMC Cancer       Date:  2017-12-15       Impact factor: 4.430

9.  Artemether suppresses cell proliferation and induces apoptosis in diffuse large B cell lymphoma cells.

Authors:  Xinying Zhao; Xudong Guo; Wenqin Yue; Jianmin Wang; Jianmin Yang; Jie Chen
Journal:  Exp Ther Med       Date:  2017-08-29       Impact factor: 2.447

Review 10.  Phytochemicals Approach for Developing Cancer Immunotherapeutics.

Authors:  Shu-Yi Yin; Ning-Sun Yang; Tien-Jen Lin
Journal:  Front Pharmacol       Date:  2017-06-19       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.